Kaspersky Lab, a leading developer of secure content management solutions, announces that Kaspersky Anti-Virus 2009 has received the Gold Malware Treatment Award from respected security software test laboratory Anti-Malware Test Lab.
More than 15 anti-virus products, including Norton AntiVirus 2009, BitDefender AntiVirus 2009 and Eset NOD32 Antivirus 3.0, participated in a series of tests evaluating the ability of the products to treat active infections. The computer used for testing was loaded with the Windows XP SP3 operating system. The tests were conducted by Anti-Malware Test Lab between 15 September and 15 October 2008 in accordance with a specially-developed methodology to test the ability of the popular anti-virus products in combating malicious programs which had already penetrated the system and were hiding traces of their activities.
According to the test results, Kaspersky Anti-Virus 2009 received the Gold Malware Treatment Award, along with five other products tested by Anti-Malware Test Lab. The rest of the participants, including McAfee VirusScan 2008, Eset NOD32 Antivirus 3.0 and BitDefender Antivirus 2009 did not pass the test and were therefore judged incapable of protecting a user's computer from active infections.
Alexander Gostev, the Head of the Global Research and Analysis Team at Kaspersky Lab, says the ability of an anti-virus program to treat infected computers has been the basic idea of anti-virus from the very beginning of the IT industry. “A modern anti-virus must not only be a tool for preventing infection but it must also be a powerful instrument which can remove active infections if other security technologies fail,” said the expert. “The test performed by Anti-Malware Test Lab demonstrates the difference in approaches of vendors in understanding the idea of anti-virus protection. However, it is not enough to detect non-active malicious code - the incidents with malicious programs such as Rustok and Sinowal have already proved this. We are pleased to see the Kaspersky Lab product among the leaders of this test. It means we not only understand the need to have a balance between proactive technologies, signature-based detection and ability to treat infected computers, but we also keep the development of all components of an anti-virus product at their highest levels.”
To read the full version of the test, please visit http://www.anti-malware-test.com/?q=node/55.
Share